BridgeBio's Heart Disease Drug Achieves Late-Stage Study Goal, Sparking Soaring Share Prices
BridgeBio Pharma's experimental drug, acoramidis, has shown significant improvement in patients with transthyretin amyloid cardiomyopathy, a rare heart disease, according to a late-stage study. The drug demonstrated a 1.8 times better outcome than placebo in preventing death, hospitalization, and improving walking distance. It also improved survival by 81% compared to the placebo and reduced heart disease-related hospitalizations by 50%. No safety concerns were identified. BridgeBio plans to submit the data to the FDA by the end of 2023 for marketing approval.
